Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Alzheimer's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Alzheimer's
    Hypertension, Markers of Inflammation In the Blood More Common in Offspring of Parents With AD - (DGNews)
    TopAbstracts in Alzheimer's 10/29/2009 - (DGNews)
    Diabetes Does Not Increase Rate of Cognitive Decline in Patients With AD - (DGNews)
    Half of Patients With Alzheimer's Disease Adhere to Cholinesterase Inhibitors After 1 Year: Presented at ANA - (DGDispatch)
    TopAbstracts in Alzheimer's 10/15/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Alzheimer's
    The Dementia Caregiver-A Primary Care Approach
    Medical Care of the Patient with Dementia

    Webcasts/CME archive

     Recent cases - Alzheimer's
      Rapid Cognitive Improvement in Alzheimer's Disease Following Perispinal Etanercept Administration
      Advances in the Pharmacotherapy of Alzheimer's Disease
      Does He Have Alzheimer's Disease?

      Cases archive
        




      my personal edition > alzheimer's > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Rivastigmine, Donepezil Combination Well Tolerated and Efficacious: Presented at IADRD

      By Peggy Peck
      Special to DG News

      STOCKHOLM, SWEDEN -- July 22, 2002 -- Preliminary findings from a study of combination therapy with rivastigmine (Exelon) and donepezil (Aricept) versus monotherapy with rivastigmine suggest that the combination is well tolerated and effective.

      The research was presented July 21 here at the 8th International Conference on Alzheimer's disease and Related Disorders.

      Joshua Shua-Haim, MD, of the Memory Disorders Institute, Manchester Township, New Jersey, United States, and colleagues in Scotland and the United States evaluated combination therapy in 27 patients and rivastigmine monotherapy in 49 patients. All patients met criteria for diagnosis of possible Alzheimer's disease or mild to moderate Alzheimer's disease and were treated for a minimum of four months with evaluations at two-month intervals.

      Average scores on the Mini Mental Status Exam (MMSE) at baseline were 16 in the combination therapy group and 19 in the monotherapy group. At one year, 33.3 percent of the patients on combination therapy were maintained on combination treatment and among these patients the average MMSE score was 1.2 above baseline measurement.

      In the group treated with rivastigmine alone, 24 patients or 48.9 percent were still compliant with the treatment after one year, but in this group the average MMSE score declined by 2.8 points from baseline.

      The reasons for stopping treatment were similar for the combination group and the rivastigmine group: adverse events (six vs. five, respectively), cost of treatment (three vs. nine), lack of efficacy (two vs. six), and recommendation from other physicians (seven vs. five).

      Among those who discontinued treatment, the combination group had an average length of treatment of four months and the single therapy group had an average of five months of treatment.



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send